Cybin Inc. Advances Mental Health Treatments with Q1 2025 Results and Key Program Updates
August 14th, 2025 1:20 PM
By: Newsworthy Staff
Cybin Inc. reports significant progress in its Phase 3 depression program and nearing completion of its Phase 2 anxiety study, highlighting advancements in next-generation mental health treatments.
Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company, has reported its unaudited Q1 2025 results, alongside key updates on its mental health treatment programs. The company has received European Clinical Trial Application and UK MHRA approval to initiate the EMBRACE study, expanding its multinational Phase 3 PARADIGM program for CYB003, aimed at the adjunctive treatment of major depressive disorder (MDD). This expansion will include approximately 550 participants, focusing on patients with moderate to severe MDD who have not responded to existing antidepressants.
Additionally, Cybin announced that enrollment for its Phase 2 study of CYB004, targeting generalized anxiety disorder, is expected to conclude this month. The company's management highlighted that recent funding efforts have positioned Cybin to advance both the CYB003 and CYB004 programs through several upcoming critical milestones. These developments underscore Cybin's commitment to addressing the significant unmet needs in mental health care through innovative treatment options.
For more detailed information on Cybin's Q1 2025 results and program updates, visit https://ibn.fm/G5r2t. Cybin's ongoing research and development efforts represent a promising avenue for the future of mental health treatment, offering hope for patients with conditions that have been difficult to treat with current therapies.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
